Macrocyclic molecules as HCV entry inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9868743
SERIAL NO

14765906

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BRISTOL-MYERS SQUIBB COMPANYROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Gillis, Eric Wallingford, US 1 2
Scola, Paul Michael Glastonbury, US 101 2080
Wang, Tao Farmington, US 1447 9693
Zhang, Zhongxing Madison, US 126 860

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 16, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 16, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00